Direct Conversion of Fibroblasts to Megakaryocyte Progenitors
Julian Pulecio,
Oriol Alejo-Valle,
Sandra Capellera-Garcia,
Marianna Vitaloni,
Paula Rio,
Eva Mejía-Ramírez,
Ilaria Caserta,
Juan A. Bueren,
Johan Flygare,
Angel Raya
Affiliations
Julian Pulecio
Center of Regenerative Medicine in Barcelona (CMRB), Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain
Oriol Alejo-Valle
Center of Regenerative Medicine in Barcelona (CMRB), Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain
Sandra Capellera-Garcia
Department of Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, 22184 Lund, Sweden
Marianna Vitaloni
Center of Regenerative Medicine in Barcelona (CMRB), Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain
Paula Rio
Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIEMAT/CIBERER-ISCIII), 28040 Madrid, Spain
Eva Mejía-Ramírez
Center of Regenerative Medicine in Barcelona (CMRB), Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain
Ilaria Caserta
Center of Regenerative Medicine in Barcelona (CMRB), Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain
Juan A. Bueren
Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIEMAT/CIBERER-ISCIII), 28040 Madrid, Spain
Johan Flygare
Department of Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, 22184 Lund, Sweden
Angel Raya
Center of Regenerative Medicine in Barcelona (CMRB), Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain
Current sources of platelets for transfusion are insufficient and associated with risk of alloimmunization and blood-borne infection. These limitations could be addressed by the generation of autologous megakaryocytes (MKs) derived in vitro from somatic cells with the ability to engraft and differentiate in vivo. Here, we show that overexpression of a defined set of six transcription factors efficiently converts mouse and human fibroblasts into MK-like progenitors. The transdifferentiated cells are CD41+, display polylobulated nuclei, have ploidies higher than 4N, form MK colonies, and give rise to platelets in vitro. Moreover, transplantation of MK-like murine progenitor cells into NSG mice results in successful engraftment and further maturation in vivo. Similar results are obtained using disease-corrected fibroblasts from Fanconi anemia patients. Our results combined demonstrate that functional MK progenitors with clinical potential can be obtained in vitro, circumventing the use of hematopoietic progenitors or pluripotent stem cells.